Diversified Trust Co Has $1.21 Million Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Diversified Trust Co increased its holdings in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 25.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 34,866 shares of the company's stock after purchasing an additional 7,039 shares during the quarter. Diversified Trust Co's holdings in BridgeBio Pharma were worth $1,205,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the business. Steward Partners Investment Advisory LLC raised its stake in shares of BridgeBio Pharma by 85.8% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 1,022 shares of the company's stock worth $28,000 after purchasing an additional 472 shares in the last quarter. GAMMA Investing LLC grew its stake in shares of BridgeBio Pharma by 71.0% in the first quarter. GAMMA Investing LLC now owns 920 shares of the company's stock valued at $32,000 after buying an additional 382 shares in the last quarter. Itau Unibanco Holding S.A. acquired a new position in BridgeBio Pharma during the fourth quarter worth $41,000. Sterling Capital Management LLC raised its position in BridgeBio Pharma by 554.6% during the fourth quarter. Sterling Capital Management LLC now owns 1,787 shares of the company's stock worth $49,000 after acquiring an additional 1,514 shares in the last quarter. Finally, GF Fund Management CO. LTD. acquired a new stake in BridgeBio Pharma in the fourth quarter valued at $109,000. Institutional investors own 99.85% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on BBIO shares. JPMorgan Chase & Co. boosted their price objective on shares of BridgeBio Pharma from $44.00 to $50.00 and gave the stock an "overweight" rating in a research note on Monday, March 24th. Redburn Atlantic began coverage on BridgeBio Pharma in a research report on Monday, March 31st. They set a "buy" rating and a $50.00 price target on the stock. HC Wainwright upped their price objective on BridgeBio Pharma from $53.00 to $56.00 and gave the company a "buy" rating in a research note on Monday, June 9th. UBS Group raised their price objective on BridgeBio Pharma from $65.00 to $72.00 and gave the company a "buy" rating in a research report on Wednesday, April 30th. Finally, Wells Fargo & Company boosted their target price on BridgeBio Pharma from $67.00 to $76.00 and gave the stock an "overweight" rating in a report on Monday. Two research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $58.85.

Insiders Place Their Bets

In related news, major shareholder Global Investors Lp Viking sold 3,500,000 shares of the firm's stock in a transaction dated Friday, June 27th. The shares were sold at an average price of $44.00, for a total transaction of $154,000,000.00. Following the transaction, the insider directly owned 18,555,375 shares of the company's stock, valued at approximately $816,436,500. This trade represents a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Andrew Lo sold 100,000 shares of the business's stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $38.50, for a total transaction of $3,850,000.00. Following the completion of the sale, the director directly owned 105,583 shares of the company's stock, valued at $4,064,945.50. This represents a 48.64% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 9,896,181 shares of company stock valued at $374,176,564 in the last three months. Insiders own 18.20% of the company's stock.

BridgeBio Pharma Stock Performance

NASDAQ:BBIO traded down $0.40 during mid-day trading on Tuesday, hitting $42.78. 2,782,196 shares of the stock were exchanged, compared to its average volume of 2,495,784. The firm's 50-day simple moving average is $37.30 and its 200 day simple moving average is $34.30. The stock has a market capitalization of $8.12 billion, a price-to-earnings ratio of -12.12 and a beta of 1.15. BridgeBio Pharma, Inc. has a fifty-two week low of $21.72 and a fifty-two week high of $45.48.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The company reported ($0.88) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.12. The firm had revenue of $36.74 million for the quarter, compared to the consensus estimate of $57.14 million. The firm's quarterly revenue was down 44.8% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.20) EPS. On average, analysts predict that BridgeBio Pharma, Inc. will post -3.67 EPS for the current fiscal year.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.